Literature DB >> 12488792

Dual effects of 5-HT4 receptor activation on GABA release from guinea pig hippocampal slices.

Clementina Bianchi1, Donata Rodi, Silvia Marino, Lorenzo Beani, Anna Siniscalchi.   

Abstract

The effects of BIMU-8, a 5-HT4 receptor agonist, were studied on GABA release in guinea pig hippocampal slices. BIMU-8 did not modify GABA outflow at rest but did display a complex action in electrically stimulated slices: at low concentrations it increased, and at higher concentrations inhibited, GABA release. These responses were competitively counteracted by GR 125487, a selective 5-HT4 receptor antagonist. The dual effects of BIMU-8 are consistent with its indirect cholinergic action since the M1 and M3 antagonist, 4-DAMP, prevented BIMU-8-elicited GABA facilitation, whereas the M2 antagonist AFDX-116 cancelled GABA inhibition. These results provide evidence that serotonin exerts a complex modulation on the GABAergic system, via 5-HT4 receptors, and suggest that the amine releases acetylcholine which, in turn, bidirectionally modulates GABA release.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12488792     DOI: 10.1097/00001756-200212030-00003

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  9 in total

1.  Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment.

Authors:  Cédric Lecoutey; Damien Hedou; Thomas Freret; Patrizia Giannoni; Florence Gaven; Marc Since; Valentine Bouet; Céline Ballandonne; Sophie Corvaisier; Aurélie Malzert Fréon; Serge Mignani; Thierry Cresteil; Michel Boulouard; Sylvie Claeysen; Christophe Rochais; Patrick Dallemagne
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-25       Impact factor: 11.205

2.  The 5-HT4 receptor levels in hippocampus correlates inversely with memory test performance in humans.

Authors:  Mette Ewers Haahr; Patrick Fisher; Klaus Holst; Karine Madsen; Christian Gaden Jensen; Lisbeth Marner; Szabols Lehel; William Baaré; Gitte Knudsen; Steen Hasselbalch
Journal:  Hum Brain Mapp       Date:  2012-06-26       Impact factor: 5.038

3.  Reduced signal transduction by 5-HT4 receptors after long-term venlafaxine treatment in rats.

Authors:  R Vidal; E M Valdizan; M T Vilaró; A Pazos; E Castro
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

Review 4.  Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders.

Authors:  Bryan L Roth; S Mohammad Hanizavareh; Andrew E Blum
Journal:  Psychopharmacology (Berl)       Date:  2003-12-02       Impact factor: 4.530

5.  Polymorphisms of genes in neurotransmitter systems were associated with alcohol use disorders in a Tibetan population.

Authors:  Yan Xu; Wan-Jun Guo; Qiang Wang; Gongga Lanzi; Ouzhu Luobu; Xiao-Hong Ma; Ying-Cheng Wang; Puo Zhen; Wei Deng; Xiang Liu; Basang Zhuoma; Xie-He Liu; Tao Li; Xun Hu
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

Review 6.  Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants.

Authors:  Alan L Pehrson; Connie Sanchez
Journal:  Drug Des Devel Ther       Date:  2015-01-19       Impact factor: 4.162

Review 7.  Alterations of Expression of the Serotonin 5-HT4 Receptor in Brain Disorders.

Authors:  Heike Rebholz; Eitan Friedman; Julia Castello
Journal:  Int J Mol Sci       Date:  2018-11-13       Impact factor: 5.923

Review 8.  Memory Disorders Related to Hippocampal Function: The Interest of 5-HT4Rs Targeting.

Authors:  Candice M Roux; Marianne Leger; Thomas Freret
Journal:  Int J Mol Sci       Date:  2021-11-08       Impact factor: 5.923

9.  The 5-hydroxytryptamine4 receptor enables differentiation of informational content and encoding in the hippocampus.

Authors:  Hannah Twarkowski; Hardy Hagena; Denise Manahan-Vaughan
Journal:  Hippocampus       Date:  2016-02-17       Impact factor: 3.899

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.